These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 1411865)

  • 1. [Hemo-rheologic changes following treatment with human recombinant erythropoietin in chronic hemodialysis patients].
    Melappioni M; Giansanti R; Boemi M; Baldassari M; Baldini S; Pierangeli T; Radicioni R; Fumelli P; Panichi N
    Minerva Urol Nefrol; 1992; 44(2):155-9. PubMed ID: 1411865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in determinants of blood rheology during treatment with haemodialysis and recombinant human erythropoietin.
    Koppensteiner R; Stockenhuber F; Jahn C; Balcke P; Minar E; Ehringer H
    BMJ; 1990 Jun; 300(6740):1626-7. PubMed ID: 2372642
    [No Abstract]   [Full Text] [Related]  

  • 3. Blood rheology in hemodialysis patients treated with recombinant human erythropoietin.
    Brunner R; Pollok M; Heidel M; Müller R; Degenhardt S; Baldamus CA
    Contrib Nephrol; 1989; 76():306-12; discussion 312-4. PubMed ID: 2582784
    [No Abstract]   [Full Text] [Related]  

  • 4. Haemorheological changes in uraemic children in response to erythropoietin treatment.
    Böhler T; Leo A; Linderkamp O; Braun A; Schärer K
    Nephrol Dial Transplant; 1993; 8(2):140-5. PubMed ID: 8384334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Improvement of hemorheologic parameters in hemodialyzed patients treated with human recombinant erythropoietin].
    Delamaire M; Durand F; Hamel D; Joyeux V; Lepogamp P; Genetet B
    J Mal Vasc; 1991; 16(3):289-94. PubMed ID: 1940657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythropoietin treatment does not compromise cardiovascular function in chronic renal failure.
    Haedersdal C; Mehlsen J; Stenver D; Nielsen B; Jeppesen L; Winther K
    Angiology; 1994 Mar; 45(3):231-4. PubMed ID: 8129205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does additional treatment with fish oil mitigate the side effects of recombinant human erythropoietin in dialysis patients?
    de Fijter CW; Popp-Snijders C; Oe LP; Tran DD; van der Meulen J; Donker AJ
    Haematologica; 1995; 80(4):332-4. PubMed ID: 7590502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rheology in whole blood and in red blood cells under recombinant human erythropoietin therapy.
    Lerche D; Schmidt R; Zoellner K; Meier W; Paulitschke M; Distler B; Klinkmann H
    Contrib Nephrol; 1989; 76():299-303; discussion 304-5. PubMed ID: 2684529
    [No Abstract]   [Full Text] [Related]  

  • 9. [Factors limiting the correction of anemia with recombinant human erythropoietin].
    Casati S
    Minerva Urol Nefrol; 1991; 43(3):121-3. PubMed ID: 1817332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of blood rheology in the pathogenesis of hypertension of hemodialysis patients treated for renal anemia with recombinant human erythropoietin.
    Baldamus CA; Steffen AM; Brunner R; Pollok M
    Contrib Nephrol; 1990; 82():79-85. PubMed ID: 2093531
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical and blood rheologic stability in erythropoietin-treated predialysis patients.
    Brown CD; Friedman EA
    Am J Nephrol; 1990; 10 Suppl 2():29-33. PubMed ID: 2260615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Erythropoietin treatment in Piedmont and Valle d'Aosta].
    Imarisio P; Biamino E; Bongiorno P; Caligaris F; Demicheli G; Montalcini G; Arnaud A
    Minerva Urol Nefrol; 1991; 43(3):143-5. PubMed ID: 1817336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Utility of recombinant human erythropoietin on the anemia of elderly hemodialysis patients].
    Ueyama H; Nakahashi H; Sawanishi K; Kuze M; Ono T
    Hinyokika Kiyo; 1992 Dec; 38(12):1429-35. PubMed ID: 1288237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of hemodialysis and recombinant human erythropoietin on determinants of blood viscosity.
    Shand BI; Buttimore AL; Lynn KL; Bailey RR; Robson RA
    Ren Fail; 1994; 16(3):407-13. PubMed ID: 8059023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of renal anaemia with recombinant human erythropoietin results in decreased red cell uptake of 45Ca.
    Linde T; Ronquist G; Sandhagen B; Wikström B; Frithz G; Pettersson L; Danielson BG
    Nephron; 1994; 68(4):419-26. PubMed ID: 7870225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of azotemic, nonoliguric, anemic patients with human recombinant erythropoietin raises whole-blood viscosity proportional to hematocrit.
    Brown CD; Kieran M; Thomas LL; Zhao ZH; Larsen R; Friedman EA
    Nephron; 1991; 59(3):394-8. PubMed ID: 1758527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Early efficacy of recombinant human erythropoietin in treatment of anemia].
    Huang S; Yang L; Huang M
    Hua Xi Yi Ke Da Xue Xue Bao; 1996 Sep; 27(3):317-9. PubMed ID: 9389072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of the anemia of hemodialysis patients with recombinant human erythropoietin.
    Schaefer RM; Kuerner B; Zech M; Denninger G; Borneff C; Heidland A
    Int J Artif Organs; 1988 Jul; 11(4):249-54. PubMed ID: 3410565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Human recombinant erythropoietin (rH-EPO) in chronic hemodialysis patients].
    Jalil R; Vaccarezza A; Jara A; Lira P; Vial S; Serrano V
    Rev Med Chil; 1990 Jun; 118(6):629-34. PubMed ID: 1775783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of recombinant human erythropoietin (rh-EPO) in the treatment of anemia in hemodialysis patients: a multicenter Italian experience.
    Buccianti G; Colombi L; Battistel V
    Haematologica; 1993; 78(2):111-7. PubMed ID: 8349186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.